ArticleBMC cancer2021

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival.

Peiyi Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.